# Mirador Therapeutics

> Mirador Therapeutics is a San Diego precision-medicine company building first- and best-in-class therapies for immune-mediated inflammatory and fibrotic diseases. Its Mirador360 engine fuses human genetics, multi-modal patient data, AI and advanced analytics to find novel targets, design combination therapies and identify the patients most likely to respond. Founded in 2024 by the former Prometheus Biosciences leadership team, Mirador launched with more than $400 million and has since raised over $650 million total.

- **Founded:** 2024
- **Headquarters:** San Diego, California, United States
- **Founders:** Mark C. McKenna (Founder, Chairman & CEO (former CEO of Prometheus Biosciences)), Olivier Laurent (Chief Scientific Officer (former CSO / Head of R&D at Prometheus Biosciences))
- **Team size:** ~96 employees
- **Products:** Mirador360, Immuno-fibrotic clinical pipeline
- **Notable:** Launched in 2024 with more than $400 million, one of the largest biotech launches of the year, Raised over $650 million in total funding within roughly two years, Closed a $250 million Series B in early 2026 with premier investors

## Products & services

- **Mirador360** — End-to-end precision discovery and development engine that harmonizes millions of patient molecular profiles, combining human genetics, multi-modal data, AI and advanced analytics to identify novel targets, design optimal combination therapies and select patients most likely to respond.
- **Immuno-fibrotic clinical pipeline** — A multi-asset pipeline of precision medicines targeting chronic immune-mediated inflammatory and fibrotic diseases including Crohn's disease, ulcerative colitis, rheumatoid arthritis and idiopathic pulmonary fibrosis, with up to ~10 clinical readouts expected by end of 2027.

## Achievements

- Launched in 2024 with more than $400 million, one of the largest biotech launches of the year
- Raised over $650 million in total funding within roughly two years
- Closed a $250 million Series B in early 2026 with premier investors
- Named an Endpoints 11 winner in 2024 for applying precision medicine to immune disease
- Built a multi-asset clinical pipeline expecting up to ~10 clinical readouts by the end of 2027

## Latest updates

- **2026-01** — Closed a $250M Series B to accelerate its multi-asset immuno-fibrotic clinical pipeline, bringing total funding above $650M.
- **2024-09** — Named an Endpoints 11 winner for applying precision medicine to immune disease.
- **2024-03** — Launched publicly with more than $400M in financing led by ARCH Venture Partners.

## Links

- Website: https://miradortx.com
- LinkedIn: https://www.linkedin.com/company/mirador-therapeutics

---

Profile page: https://yespress.io/mirador-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-08